Premium
TREOSULFAN (DIHYDROXYBUSULPHAN) IN THE MANAGEMENT OF OVARIAN CARCINOMA
Author(s) -
Fennelly J.
Publication year - 1977
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/j.1471-0528.1977.tb12581.x
Subject(s) - treosulfan , ovarian carcinoma , medicine , ascites , ovarian cancer , oncology , carcinoma , cancer , chemotherapy , busulfan , cyclophosphamide
Summary Of 36 patients with ovarian carcinoma treated with treosulfan (dihydroxybusulphan) 30·5 per cent had a complete response for a mean of 19·0 months and 33·3 per cent had a partial response. Treosulfan may have a role in the management of ascites associated with ovarian neoplasm.